Nordea Investment Management AB Boosts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Nordea Investment Management AB boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 31.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,985 shares of the medical research company’s stock after purchasing an additional 480 shares during the quarter. Nordea Investment Management AB’s holdings in Bio-Rad Laboratories were worth $828,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Ardevora Asset Management LLP increased its holdings in shares of Bio-Rad Laboratories by 9.5% in the 4th quarter. Ardevora Asset Management LLP now owns 114,147 shares of the medical research company’s stock valued at $47,998,000 after acquiring an additional 9,918 shares during the last quarter. MML Investors Services LLC increased its holdings in shares of Bio-Rad Laboratories by 13.5% in the 3rd quarter. MML Investors Services LLC now owns 7,959 shares of the medical research company’s stock valued at $3,320,000 after acquiring an additional 944 shares during the last quarter. Guggenheim Capital LLC increased its holdings in shares of Bio-Rad Laboratories by 18.6% in the 3rd quarter. Guggenheim Capital LLC now owns 1,592 shares of the medical research company’s stock valued at $664,000 after acquiring an additional 250 shares during the last quarter. Dupont Capital Management Corp grew its stake in Bio-Rad Laboratories by 82.0% during the 3rd quarter. Dupont Capital Management Corp now owns 273 shares of the medical research company’s stock worth $114,000 after buying an additional 123 shares during the last quarter. Finally, Aigen Investment Management LP boosted its position in Bio-Rad Laboratories by 49.8% during the 3rd quarter. Aigen Investment Management LP now owns 713 shares of the medical research company’s stock worth $297,000 after acquiring an additional 237 shares during the period. 64.35% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Stock Up 2.2 %

NYSE:BIO opened at $372.51 on Friday. The firm has a market capitalization of $11.02 billion, a price-to-earnings ratio of -56.96 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 1-year low of $344.63 and a 1-year high of $572.70. The company has a current ratio of 5.56, a quick ratio of 4.28 and a debt-to-equity ratio of 0.12. The business’s fifty day moving average price is $458.22 and its 200 day moving average price is $441.30.

Bio-Rad Laboratories (NYSE:BIO – Get Rating) last posted its quarterly earnings results on Thursday, May 4th. The medical research company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.10. The firm had revenue of $676.80 million for the quarter, compared to analyst estimates of $689.28 million. Bio-Rad Laboratories had a positive return on equity of 4.10% and a negative net margin of 7.01%. Bio-Rad Laboratories’s quarterly revenue was down 3.3% on a year-over-year basis. During the same period in the previous year, the firm earned $4.94 earnings per share. On average, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 15.91 earnings per share for the current fiscal year.

Insider Activity at Bio-Rad Laboratories

In related news, EVP Timothy S. Ernst sold 1,746 shares of the company’s stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $486.43, for a total transaction of $849,306.78. Following the transaction, the executive vice president now directly owns 2,671 shares of the company’s stock, valued at $1,299,254.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 17.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. TheStreet upgraded Bio-Rad Laboratories from a “d+” rating to a “c” rating in a report on Thursday, February 16th. Credit Suisse Group upped their target price on Bio-Rad Laboratories from $640.00 to $680.00 and gave the company an “outperform” rating in a report on Friday, February 17th. StockNews.com initiated coverage on Bio-Rad Laboratories in a report on Thursday, March 16th. They set a “buy” rating for the company. Finally, Royal Bank of Canada upped their target price on Bio-Rad Laboratories from $571.00 to $579.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $653.00.

Bio-Rad Laboratories Profile

(Get Rating)

Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.